The Global Health Body Issues Warning Over Severe Lack of Obesity Jabs

Fewer than a tenth of individuals that would benefit from weight-loss injections like Wegovy have access to them, warns the global health agency as it releases its first recommendations on the therapies.

Given in excess of 1,000,000,000 people worldwide now obese, it is advocating for increased and just access to GLP-1 medication.

According to projections, over two billion are projected to be obese by 2030 unless action is taken.

"Our new guidance acknowledges that obesity is a chronic disease that can be addressed with holistic and continuous support," stated the agency's head Tedros Adhanom Ghebreyesus.

Substantial prices, limited production capacity, and distribution challenges are key barriers to universal availability to the jabs that can help people shift substantial body mass, notes the agency.

Weight-Loss Drug Scarcity

Despite the current best projected case, the production of GLP-1 therapies might only reach around 100 million people – fewer than 10% of those who need them, according to the WHO.

The guideline calls on countries and companies to expand availability, via measures such as voluntary licensing.

Exclusive production rights on semaglutide – the primary ingredient of the drug Wegovy – is set to lapse in multiple nations in 2026.

The Way Weight-Loss Jabs Work

These medications mimick a natural hormone to slow digestion, reduce hunger and increase feelings of fullness so individuals reduce food intake.

Patients usually begin shedding pounds after several weeks of beginning the weekly injections.

Studies suggests patients may put most of the weight back on a year later of stopping the drug, because their normal food cravings resume.

To be carrying excess weight elevates your likelihood for developing health problems, like type 2 diabetes, heart disease, brain attack, and certain cancers.

Obesity affects people in countries worldwide and was responsible for millions of deaths worldwide in 2024, per the WHO.